Helical Tomotherapy for the Treatment of Anal Canal Cancer: A Dosimetric Comparison with 3D Conformal Radiotherapy

Abstract

Aims and Background

The standard treatment of anal canal cancer (ACC) is combined chemotherapy and radiation therapy (RT), which is complex because of the shape of the target volumes and the need to minimize the irradiation of normal pelvic structures. In this study we compared the dosimetric results of helical tomotherapy (HT) plans with traditional 3D conformal RT (3DRT) plans for the treatment of ACC.

Methods and Study Design

Twelve patients (median age 57 years, range 38–83; F/M 8/4) treated with HT and concurrent chemotherapy for locally advanced ACC were selected. All had histologically confirmed squamous-cell carcinoma. A clinical target volume including the tumor and pelvic and inguinal lymph nodes was treated with HT to a total dose of 36 Gy in 1.8-Gy daily fractions. Then a sequential boost of 23.4 Gy in 1.8-Gy daily fractions (total dose 59.4 Gy) was delivered to the tumor and involved nodes. For all 12 patients, 3DRT plans were generated for comparison. Treatment plans were evaluated by means of standard dose-volume histograms. Dose coverage of the planning target volumes (PTVs), homogeneity index (HI), and mean doses to organs at risk (OARs) were compared.

Results

The coverage of PTV was comparable between the two treatment plans. HI was better in the HT vs. 3DRT plans (1.25 and 3.57, respectively; p<0.0001). HT plans resulted in better sparing of OARs (p<0.0001).

Conclusions

HT showed superior target dose conformality and significant sparing of pelvic structures compared with 3DRT. Further investigation should determine if these dosimetric improvements will improve clinical outcomes regarding locoregional control, survival, and treatment-related acute and late morbidity.

Keywords

Anal canal cancer 3D Conformal radiotherapy Helical tomotherapy

Get full access to this article

View all access options for this article.

References

Menkarios

Azria

Laliberté

Optimal organ-sparing intensity-modulated radiation therapy (IMRT) regimen for the treatment of locally advanced anal canal carcinoma: a comparison of conventional and IMRT plans. Radiat Oncol. 2007; 2(1): 41.

Intensity Modulated Radiation Therapy Collaborative Working Group. Intensity-modulated radiotherapy: current status and issues of interest. Int J Radiat Oncol Biol Phys. 2001; 51(4): 880–914.

Mackie

T.R.

Holmes

Swerdloff

Tomotherapy: a new concept for the delivery of dynamic conformal radiotherapy. Med Phys. 1993; 20(6): 1709–1719.

Ruchala

K.J.

Olivera

G.H.

Kapatoes

J.M.

Schloesser

E.A.

Reckwerdt

P.J.

Mackie

T.R.

Megavoltage CT image reconstruction during tomotherapy treatments. Phys Med Biol. 2000; 45(12): 3545–3562.

Chen

Y.J.

Liu

Tsai

P.T.

Organ sparing by conformal avoidance intensity-modulated radiation therapy for anal cancer: dosimetric evaluation of coverage of pelvis and inguinal/femoral nodes. Int J Radiat Oncol Biol Phys. 2005; 63(1): 274–281.

Milano

M.T.

Jani

A.B.

Farrey

K.J.

Rash

Heimann

Chmura

S.J.

Intensity-modulated radiation therapy (IMRT) in the treatment of anal cancer: toxicity and clinical outcome. Int J Radiat Oncol Biol Phys. 2005; 63(2): 354–361.

Myerson

R.J.

Garofalo

M.C.

El Naqa

Elective clinical target volumes for conformal therapy in anorectal cancer: a Radiation Therapy Oncology Group consensus panel contouring atlas. Int J Radiat Oncol Biol Phys. 2009; 74(3): 824–830.

Bartelink

Roelofsen

Eschwege

Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol. 1997; 15(5): 2040–2049.

Joseph

K.J.

Syme

Small

A treatment planning study comparing helical tomotherapy with intensity-modulated radiotherapy for the treatment of anal cancer. Radiother Oncol. 2010; 94(1): 60–66.

10.

Northover

Glynne-Jones

Sebag-Montefiore

Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I). Br J Cancer. 2010; 102(7): 1123–1128.

11.

Flam

John

Pajak

T.F.

Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized Intergroup study. J Clin Oncol. 1996; 14(9): 2527–2539.

12.

Ajani

J.A.

Winter

K.A.

Gunderson

L.L.

Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JAMA. 2008; 299(16): 1914–1921.

13.

Kachnic

L.A.

Winter

Myerson

R.J.

RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal. Int J Radiat Oncol Biol Phys. 2013; 86(1): 27–33.

14.

Matzinger

Roelofsen

Mineur

; EORTC Radiation Oncology and Gastrointestinal Tract Cancer Groups. Mitomycin C with continuous fluorouracil or with cisplatin in combination with radiotherapy for locally advanced anal cancer (European Organisation for Research and Treatment of Cancer phase II study 22011–40014). Eur J Cancer. 2009; 45(16): 2782–2791.

15.

Clivio

Fogliata

Franzetti-Pellanda

Volumetric-modulated arc radiotherapy for carcinomas of the anal canal: A treatment planning comparison with fixed field IMRT. Radiother Oncol. 2009; 92(1): 118–124.

16.

Vieillot

Azria

Lemanski

Plan comparison of volumetric-modulated arc therapy (RapidArc) and conventional intensity-modulated radiation therapy (IMRT) in anal canal cancer. Radiat Oncol. 2010; 5(1): 92.

17.

Salama

J.K.

Meli

L.K.

Schomas

D.A.

Concurrent chemotherapy and intensity-modulated radiation therapy for anal canal cancer patients: a multicenter experience. J Clin Oncol. 2007; 25(29): 4581–4586.

18.

Bazan

J.G.

Hara

Hsu

Intensity-modulated radiation therapy versus conventional radiation therapy for squamous cell carcinoma of the anal canal. Cancer. 2011; 117(15): 3342–3351.

19.

Vieillot

Fenoglietto

Lemanski

IMRT for locally advanced anal cancer: clinical experience of the Montpellier Cancer Center. Radiat Oncol. 2012; 7(1): 45.

20.

Herman

J.M.

Thomas

C.R.

Jr.

RTOG 0529: Intensity modulated radiation therapy and anal cancer, a step in the right direction?

Int J Radiat Oncol Biol Phys. 2013; 86(1): 8–10.

21.

Hodges

J.C.

Beg

M.S.

Das

Meyer

Cost-effectiveness analysis of intensity modulated radiation therapy versus 3-dimensional conformal radiation therapy for anal cancer. Int J Radiat Oncol Biol Phys. 2014; 89(4): 773–783.

22.

Glynne-Jones

Nilsson

P.J.

Aschele

; European Society for Medical Oncology (ESMO); European Society of Surgical Oncology (ESSO); European Society of Radiotherapy and Oncology (ESTRO). Anal cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. Eur J Surg Oncol. 2014; 40(10): 1165–1176.

23.

National Comprehensive Cancer Network. Anal carcinoma (version 1.2015). http://www.nccn.org/professionals/physician_gls/pdf/anal.pdf. Accessed September 30, 2014.

24.

De Bari

Bouchaab

Péguret

Helical intensity-modulated radiation therapy with daily image guidance in the treatment of anal canal cancer. Int J Radiat Oncol Biol Phys. 2014; 90(1 Suppl 1): S397–S398.

25.

Glynne-Jones

Sebag-Montefiore

Adams

; UKCCCR Anal Cancer Trial Working Party. “Mind the gap”—the impact of variations in the duration of the treatment gap and overall treatment time in the first UK Anal Cancer Trial (ACT I). Int J Radiat Oncol Biol Phys. 2011; 81(5): 1488–1494.

26.

Deutsch

Lemanski

Pignon

J.P.

Unexpected toxicity of cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: results of the UNICANCER ACCORD 16 phase II trial. Ann Oncol. 2013; 24(11): 2834–2838.